Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Scott Braunstein Joins Aisling Capital as Operating Partner

August 10, 2015
NEW YORK, Aug. 10, 2015 /PRNewswire/ -- Aisling Capital, a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies, announced that…
READ MORE

Aimmune Therapeutics Announces Pricing of Initial Public Offering

August 5, 2015
BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 5, 2015-- Aimmune Therapeutics, Inc. today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of…
READ MORE

Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis

August 3, 2015
Two Identical Studies to Enroll a Combined Total of 660 Patients Topline Phase 3 Data Expected in the Second Half of 2016 Represents Dermira's Second Product Candidate in Phase 3…
READ MORE